Replies to post #250417 on Biotech Values

[DewDiligence]

BMY acquires TSVT for $3.00/sh cash—a 79% premium to yesterday’s close:

https://www.businesswire.com/news/home/20250310482749/en

The nominal deal value is a $102M.

BMY and TSVT are partners on Abecma. TSVT divested all non-Abecma assets in Jan 2024 for a paltry $5M (#msg-173732133).

TSVT is the 2021 oncology spinoff from BLUE. BLUE itself was acquired by a private equity firm in a Feb 2025 takeunder (#msg-175838971.